Free Trial

Revolution Medicines (RVMD) Stock Price, News & Analysis

Revolution Medicines logo
$38.02 -0.48 (-1.25%)
Closing price 04:00 PM Eastern
Extended Trading
$38.02 -0.01 (-0.01%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Revolution Medicines Stock (NASDAQ:RVMD)

Key Stats

Today's Range
$37.85
$38.47
50-Day Range
$36.44
$42.01
52-Week Range
$29.17
$62.40
Volume
1.40 million shs
Average Volume
1.66 million shs
Market Capitalization
$7.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.00
Consensus Rating
Buy

Company Overview

Revolution Medicines Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

RVMD MarketRank™: 

Revolution Medicines scored higher than 91% of companies evaluated by MarketBeat, and ranked 76th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Revolution Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Revolution Medicines has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Revolution Medicines' stock forecast and price target.
  • Earnings Growth

    Earnings for Revolution Medicines are expected to decrease in the coming year, from ($3.49) to ($3.99) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Revolution Medicines is -9.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Revolution Medicines is -9.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Revolution Medicines has a P/B Ratio of 2.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Revolution Medicines' valuation and earnings.
  • Percentage of Shares Shorted

    9.42% of the float of Revolution Medicines has been sold short.
  • Short Interest Ratio / Days to Cover

    Revolution Medicines has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in Revolution Medicines has recently decreased by 11.34%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Revolution Medicines does not currently pay a dividend.

  • Dividend Growth

    Revolution Medicines does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.42% of the float of Revolution Medicines has been sold short.
  • Short Interest Ratio / Days to Cover

    Revolution Medicines has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in Revolution Medicines has recently decreased by 11.34%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Revolution Medicines has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Revolution Medicines this week, compared to 7 articles on an average week.
  • Search Interest

    Only 2 people have searched for RVMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Revolution Medicines insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.20% of the stock of Revolution Medicines is held by insiders.

  • Percentage Held by Institutions

    94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Revolution Medicines' insider trading history.
Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

RVMD Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Leerink Partnrs Issues Positive Estimate for RVMD Earnings
See More Headlines

RVMD Stock Analysis - Frequently Asked Questions

Revolution Medicines' stock was trading at $43.74 at the beginning of 2025. Since then, RVMD stock has decreased by 13.1% and is now trading at $38.02.

Revolution Medicines, Inc. (NASDAQ:RVMD) issued its quarterly earnings data on Wednesday, May, 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by $0.01.
Read the conference call transcript
.

Revolution Medicines (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Revolution Medicines' top institutional shareholders include Harbor Capital Advisors Inc. (0.03%). Insiders that own company stock include Thilo Schroeder, Mark A Goldsmith, Stephen Michael Kelsey, Margaret A Horn, Jack Anders, Lorence H Kim, Jeff Cislini, Xiaolin Wang, Sushil Patel and Barbara Weber.
View institutional ownership trends
.

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Revolution Medicines investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/07/2025
Today
7/11/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RVMD
CIK
1628171
Fax
N/A
Employees
250
Year Founded
N/A

Price Target and Rating

High Price Target
$80.00
Low Price Target
$55.00
Potential Upside/Downside
+78.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$600.09 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-37.06%
Return on Assets
-32.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.46
Quick Ratio
13.46

Sales & Book Value

Annual Sales
$11.58 million
Price / Sales
611.57
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$13.47 per share
Price / Book
2.82

Miscellaneous

Outstanding Shares
186,270,000
Free Float
170,994,000
Market Cap
$7.08 billion
Optionable
Optionable
Beta
1.06
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:RVMD) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners